# US 2014/0155816 A1 · Method for treating brain injury or stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155816 A1
- Document ID: US20140155816A1
- Status: Published application
- Kind: A1
- Application number: 14/049,031
- Filed: 2013-10-08
- Published: 2014-06-05
- Earliest claimed: 2012-10-09
- Assignees: Eu Sol Biotech Co., Ltd.
- Applicants: EU SOL Biotech Co., Ltd.
- Inventors: HENRICH CHENG; MAY-JYWAN TSAI; SHIANG-SUO HUANG; SHIH-LING HUANG
- Web page: https://patentgrep.com/patent/US20140155816A1

## CPC

- A61M 1/1678: {intracorporal (peritoneal dialysis A61M1/28)}
- A61B 5/14528: {invasively}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61M 1/1654: {Dialysates therefor}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61M 2202/0464: Cerebrospinal fluid
- A61M 2210/0693: Brain, cerebrum
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for treating brain injury or stroke in a subject in need thereof, comprising implanting a microdialysis probe into the injury or insult core of the subject and perfusing the probe with an oncotic agent dissolved in a physiologically acceptable buffer, wherein the microdialysis probe comprises a dialysis membrane with a molecular weight cutoff less than the molecular weight of the oncotic agent.

## Claims

### Claim 1

A method for treating brain injury or stroke in a subject in need thereof, comprising implanting a microdialysis probe into the injury or insult core of the subject and perfusing the probe with an oncotic agent dissolved in a physiologically acceptable buffer, wherein the microdialysis probe comprises a dialysis membrane with a molecular weight cutoff less than the molecular weight of the oncotic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the physiologically acceptable buffer is selected from the group consisting of artificial cerebrospinal fluid (aCSF), Ringer's solution, and normal saline.

### Claim 3 (depends on 1)

The method of claim 1, wherein the oncotic agent is bovine serum albumin or human serum albumin.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dialysis membrane has a molecular weight cutoff of less than 67 kDa.

### Claim 5 (depends on 1)

The method of claim 1, wherein the stroke is caused by cerebral ischemia.

### Claim 6 (depends on 1)

The method of claim 1, which further comprises administering to the subject a thrombolytic drug and/or a neuroprotective agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neuroprotective agent is selected from the group consisting of acidic fibroblast growth factor (aFGF), basic FGF (bFGF), PDGF, EGF, HGF, CNTF, NGF, NT3, NT4, BDNF, GDNF, TGFβ, BMPs, PACAP and a combination thereof.

### Claim 8 (depends on 2)

The method of claim 2, wherein the aCSF comprises sodium ions at a concentration of 150 mM, potassium ions at a concentration of 3 mM, calcium ions at a concentration of 1.4 mM, magnesium ions at a concentration of 0.8 mM, phosphor ions at a concentration of 1 mM, chloride ions a concentration of 155 mM.

### Claim 9 (depends on 1)

The method of claim 1, wherein the perfusion is conducted at a rate of 0.1-10 μL/min.

### Claim 10 (depends on 9)

The method of claim 9, wherein the perfusion is conducted at a rate of 5 μL/min.

### Claim 11

A method for treating brain injury or stroke in a subject in need thereof, comprising:
(a) implanting a microdialysis probe into the injury or insult core of the subject and perfusing the probe with an oncotic agent dissolved in a physiologically acceptable buffer, wherein the microdialysis probe comprises a dialysis membrane with a molecular weight cutoff less than the molecular weight of the oncotic agent; and
(b) topically administering a therapeutically effective amount of a neuroprotective agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein the neuroprotective agent is selected from the group consisting of acidic fibroblast growth factor (aFGF), basic FGF (bFGF), PDGF, EGF, HGF, CNTF, NGF, NT3, NT4, BDNF, GDNF, TGFβ, BMPs, PACAP and a combination thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the physiologically acceptable buffer is selected from the group consisting of artificial cerebrospinal fluid (aCSF), Ringer's solution, and normal saline.

### Claim 14 (depends on 11)

The method of claim 11, wherein the oncotic agent is bovine serum albumin or human serum albumin, and the dialysis membrane is a 20 kDa cutoff membrane.

### Claim 15 (depends on 11)

The method of claim 11, wherein the stroke is caused by cerebral ischemia.

### Claim 16 (depends on 11)

The method of claim 11, wherein the neuroprotective agent is mixed with a slow-release carrier.

### Claim 17 (depends on 16)

The method of claim 16, wherein the slow-release carrier is fibrin glue.

### Claim 18 (depends on 11)

The method of claim 11, wherein step (a) is performed simultaneously with, before, or after step (b).